デフォルト表紙
市場調査レポート
商品コード
1050980

性別違和の世界市場-市場の洞察、疫学、市場予測(2032年)

Gender dysphoria - Market Insight, Epidemiology and Market Forecast -2032

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
性別違和の世界市場-市場の洞察、疫学、市場予測(2032年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 200 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の性別違和市場について調査分析し、市場概要、上市されている製品、市場分析など、体系的な情報を提供しています。

目次

第1章 主な洞察

第2章 性別違和のエグゼクティブサマリー

第3章 性別違和の競合情報分析

第4章 性別違和:一目でわかる市場概要

  • 性別違和の総市場シェア(%)分布(2019年)
  • 性別違和の総市場シェア(%)分布(2032年)

第5章 性別違和:疾患の背景と概要

  • イントロダクション
  • 徴候と症状
  • 病態生理学
  • 危険因子
  • 診断

第6章 ペイシェントジャーニー

第7章 性別違和の疫学と患者数

  • 疫学の主な調査結果
  • 仮定と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国の性別違和の疫学シナリオ(2019年~2032年)
  • 米国の疫学
    • 米国の性別違和の疫学シナリオ(2019年~2032年)
  • EU5ヶ国の疫学
    • ドイツの疫学
    • フランスの疫学
    • イタリアの疫学
    • スペインの疫学
    • 英国の疫学
    • 日本の疫学

第8章 治療アルゴリズム、現在の治療、医療行為

  • 性別違和の治療と管理
  • 性別違和の治療アルゴリズム

第9章 アンメットニーズ

第10章 性別違和治療の主要評価項目

第11章 上市されている製品

  • 主要7ヶ国の上市されている製品一覧
  • 薬剤名:会社名
    • 製品説明
    • 規制のマイルストーン
    • その他の開発活動
    • 重要な臨床試験
    • ピボタル臨床試験の概要
  • リストの続き

第12章 新規治療薬

  • 主なクロス競合
  • 薬剤名:会社名
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • リストの続き

第13章 性別違和:7つの主要な市場分析

  • 主な調査結果
  • 主要7ヶ国の性別違和の市場規模
  • 主要7ヶ国の性別違和の市場規模:治療法別

第14章 属性分析

第15章 主要7ヶ国:市場の展望

  • 米国の市場規模
    • 性別違和の米国の総市場規模
    • 性別違和の米国の市場規模:治療法別
  • EU5ヶ国の市場規模と展望
  • ドイツの市場規模
    • 性別違和のドイツの総市場規模
    • 性別違和のドイツの市場規模:治療法別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模
    • 性別違和の英国の総市場規模
    • 性別違和の英国の市場規模:治療法別
  • 日本市場の展望
    • 日本市場の規模

第16章 性別違和のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

  • 参考文献
  • レポートの調査手法

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Gender dysphoria Epidemiology (2019-2032)
  • Table 2: 7MM Gender dysphoria Diagnosed and Treatable Cases (2019-2032)
  • Table 3: Gender dysphoria Epidemiology in the United States (2019-2032)
  • Table 4: Gender dysphoria Diagnosed and Treatable Cases in the United States (2019-2032)
  • Table 5: Gender dysphoria Epidemiology in Germany (2019-2032)
  • Table 6: Gender dysphoria Diagnosed and Treatable Cases in Germany (2019-2032)
  • Table 7: Gender dysphoria Epidemiology in France (2019-2032)
  • Table 8: Gender dysphoria Diagnosed and Treatable Cases in France (2019-2032)
  • Table 9: Gender dysphoria Epidemiology in Italy (2019-2032)
  • Table 10: Gender dysphoria Diagnosed and Treatable Cases in Italy (2019-2032)
  • Table 11: Gender dysphoria Epidemiology in Spain (2019-2032)
  • Table 12: Gender dysphoria Diagnosed and Treatable Cases in Spain (2019-2032)
  • Table 13: Gender dysphoria Epidemiology in the UK (2019-2032)
  • Table 14: Gender dysphoria Diagnosed and Treatable Cases in the UK (2019-2032)
  • Table 15: Gender dysphoria Epidemiology in Japan (2019-2032)
  • Table 16: Gender dysphoria Diagnosed and Treatable Cases in Japan (2019-2032)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Table 20: Region-wise Market Size in USD, Million (2019-2032)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Table 22: United States Market Size in USD, Million (2019-2032)
  • Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Table 24: Germany Market Size in USD, Million (2019-2032)
  • Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Table 26: France Market Size in USD, Million (2019-2032)
  • Table 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Table 28: Italy Market Size in USD, Million (2019-2032)
  • Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Table 30: Spain Market Size in USD, Million (2019-2032)
  • Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Table 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Table 34: Japan Market Size in USD, Million (2019-2032)
  • Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Gender dysphoria Epidemiology (2019-2032)
  • Figure 2: 7MM Gender dysphoria Diagnosed and Treatable Cases (2019-2032)
  • Figure 3: Gender dysphoria Epidemiology in the United States (2019-2032)
  • Figure 4: Gender dysphoria Diagnosed and Treatable Cases in the United States (2019-2032)
  • Figure 5: Gender dysphoria Epidemiology in Germany (2019-2032)
  • Figure 6: Gender dysphoria Diagnosed and Treatable Cases in Germany (2019-2032)
  • Figure 7: Gender dysphoria Epidemiology in France (2019-2032)
  • Figure 8: Gender dysphoria Diagnosed and Treatable Cases in France (2019-2032)
  • Figure 9: Gender dysphoria Epidemiology in Italy (2019-2032)
  • Figure 10: Gender dysphoria Diagnosed and Treatable Cases in Italy (2019-2032)
  • Figure 11: Gender dysphoria Epidemiology in Spain (2019-2032)
  • Figure 12: Gender dysphoria Diagnosed and Treatable Cases in Spain (2019-2032)
  • Figure 13: Gender dysphoria Epidemiology in the UK (2019-2032)
  • Figure 14: Gender dysphoria Diagnosed and Treatable Cases in the UK (2019-2032)
  • Figure 15: Gender dysphoria Epidemiology in Japan (2019-2032)
  • Figure 16: Gender dysphoria Diagnosed and Treatable Cases in Japan (2019-2032)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Figure 20: Region-wise Market Size in USD, Million (2019-2032)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Figure 22: United States Market Size in USD, Million (2019-2032)
  • Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Figure 24: Germany Market Size in USD, Million (2019-2032)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Figure 26: France Market Size in USD, Million (2019-2032)
  • Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Figure 28: Italy Market Size in USD, Million (2019-2032)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Figure 30: Spain Market Size in USD, Million (2019-2032)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Figure 34: Japan Market Size in USD, Million (2019-2032)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

The list of figures is not exhaustive; the final content may vary

目次
Product Code: DIMI1091

DelveInsight's "Gender dysphoria- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gender dysphoria, historical and forecasted epidemiology as well as the Gender dysphoria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gender dysphoria market report provides current treatment practices, emerging drugs, Gender dysphoria market share of the individual therapies, current and forecasted Gender dysphoria market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Gender dysphoria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Gender dysphoria Disease Understanding and Treatment Algorithm

The DelveInsight Gender dysphoria market report gives a thorough understanding of the Gender dysphoria by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Gender dysphoria.

Treatment

It covers the details of conventional and current medical therapies available in the Gender dysphoria market for the treatment of the condition. It also provides Gender dysphoria treatment algorithms and guidelines in the United States, Europe, and Japan.

Gender dysphoria Epidemiology

The Gender dysphoria epidemiology division provide insights about historical and current Gender dysphoria patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Gender dysphoria epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Gender dysphoria Epidemiology

The epidemiology segment also provides the Gender dysphoria epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Gender dysphoria Drug Chapters

Drug chapter segment of the Gender dysphoria report encloses the detailed analysis of Gender dysphoria marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Gender dysphoria clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Gender dysphoria treatment.

Gender dysphoria Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Gender dysphoria treatment.

Gender dysphoria Market Outlook

The Gender dysphoria market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Gender dysphoria market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Gender dysphoria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Gender dysphoria market in 7MM is expected to change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Gender dysphoria market in 7MM.

The United States Market Outlook

This section provides the total Gender dysphoria market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Gender dysphoria market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Gender dysphoria market size and market size by therapies in Japan is also mentioned.

Gender dysphoria Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Gender dysphoria market or expected to get launched in the market during the study period 2019-2032. The analysis covers Gender dysphoria market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Gender dysphoria Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Gender dysphoria key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Gender dysphoria emerging therapies.

Reimbursement Scenario in Gender dysphoria

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Gender dysphoria domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Gender dysphoria market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Gender dysphoria Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Gender dysphoria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Gender dysphoria epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Gender dysphoria are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Gender dysphoria market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gender dysphoria market

Report Highlights:

  • In the coming years, Gender dysphoria market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gender dysphoria R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Gender dysphoria. Launch of emerging therapies will significantly impact the Gender dysphoria market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Gender dysphoria
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Gender dysphoria Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Gender dysphoria Pipeline Analysis
  • Gender dysphoria Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Gender dysphoria Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Gender dysphoria Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Gender dysphoria Report Assessment

Current Treatment Practices

  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Gender dysphoria market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Gender dysphoria total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Gender dysphoria market size during the forecast period (2019-2032)?
  • At what CAGR, the Gender dysphoria market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Gender dysphoria market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Gender dysphoria market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Gender dysphoria?
  • What is the historical Gender dysphoria patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Gender dysphoria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Gender dysphoria?
  • Out of all 7MM countries, which country would have the highest prevalent population of Gender dysphoria during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Gender dysphoria treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Gender dysphoria in the USA, Europe, and Japan?
  • What are the Gender dysphoria marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Gender dysphoria?
  • How many therapies are developed by each company for Gender dysphoria treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Gender dysphoria treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Gender dysphoria therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gender dysphoria and their status?
  • What are the key designations that have been granted for the emerging therapies for Gender dysphoria?
  • What are the global historical and forecasted market of Gender dysphoria?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Gender dysphoria market
  • To understand the future market competition in the Gender dysphoria market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Gender dysphoria in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Gender dysphoria market
  • To understand the future market competition in the Gender dysphoria market

Table of Contents

1. Key Insights

2. Executive Summary of Gender dysphoria

3. Competitive Intelligence Analysis for Gender dysphoria

4. Gender dysphoria: Market Overview at a Glance

  • 4.1. Gender dysphoria Total Market Share (%) Distribution in 2019
  • 4.2. Gender dysphoria Total Market Share (%) Distribution in 2032

5. Gender dysphoria: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Gender dysphoria Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Gender dysphoria Epidemiology Scenario in the 7MM (2019-2032)
  • 7.4. United States Epidemiology
    • 7.4.1. Gender dysphoria Epidemiology Scenario in the United States (2019-2032)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Gender dysphoria Epidemiology Scenario in Germany (2019-2032)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Gender dysphoria Epidemiology Scenario in France (2019-2032)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Gender dysphoria Epidemiology Scenario in Italy (2019-2032)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Gender dysphoria Epidemiology Scenario in Spain (2019-2032)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Gender dysphoria Epidemiology Scenario in the United Kingdom (2019-2032)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Gender dysphoria Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Gender dysphoria Treatment and Management
  • 8.2. Gender dysphoria Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Gender dysphoria Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial
  • List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • List to be continued in report

13. Gender dysphoria: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Gender dysphoria Market Size in 7MM
  • 13.3. Gender dysphoria Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Gender dysphoria Total Market Size in the United States
    • 15.1.2. Gender dysphoria Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Gender dysphoria Total Market Size in Germany
    • 15.3.2. Gender dysphoria Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Gender dysphoria Total Market Size in France
    • 15.4.2. Gender dysphoria Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Gender dysphoria Total Market Size in Italy
    • 15.5.2. Gender dysphoria Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Gender dysphoria Total Market Size in Spain
    • 15.6.2. Gender dysphoria Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Gender dysphoria Total Market Size in the United Kingdom
    • 15.7.2. Gender dysphoria Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Gender dysphoria Total Market Size in Japan
    • 15.8.3. Gender dysphoria Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Gender dysphoria

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

  • The table of contents is not exhaustive; the final content may vary.